Dual targeting of 3CLpro and PLpro of SARS-CoV-2: A novel structure-based design approach to treat COVID-19
With the rapid growth of the COVID-19 (coronavirus disease 2019) pandemic across the globe, therapeutic attention must be directed to fight the novel severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). However, developing new antiviral drugs and vaccines is time-consuming, so one of the be...
Main Authors: | Sajjan Rajpoot, Manikandan Alagumuthu, Mirza S. Baig |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-01-01
|
Series: | Current Research in Structural Biology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2665928X20300258 |
Similar Items
-
Potential inhibitors of SARS-CoV-2 (COVID 19) proteases PLpro and Mpro/ 3CLpro: molecular docking and simulation studies of three pertinent medicinal plant natural components
by: Devvret Verma, et al.
Published: (2021-01-01) -
Computational Studies of SARS-CoV-2 3CLpro: Insights from MD Simulations
by: Alessandro Grottesi, et al.
Published: (2020-07-01) -
Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach
by: Zahra Molavi, et al.
Published: (2021-06-01) -
Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors
by: Wei-Chung Chiou, et al.
Published: (2021-01-01) -
Potential SARS-CoV-2 3CLpro inhibitors from chromene, flavonoid and hydroxamic acid compound based on FRET assay, docking and pharmacophore studies
by: Maywan Hariono, et al.
Published: (2021-01-01)